

## Fragment Based Drug Discovery: A Revolution in Discovery Chemistry

### Management

**Harren Jhoti, PhD**  
Founder and CEO

**Martin Buckland, DPhil MBA**  
Chief Business Officer

**David Rees, PhD**  
Senior VP Medicinal Chemistry

**Neil Thompson, PhD**  
Senior VP Biology

**Lyn Leaper, PhD, EPA**  
Senior VP Intellectual Property

**Neil Jones, BSc FCA**  
VP Finance and Admin

**John Lyons, PhD**  
VP Translational R&D

**Chris Murray, PhD**  
VP Discovery Technology

**Jeff Yon, PhD**  
VP Structural Biology

**Glyn Williams, DPhil**  
VP Biophysics

### Board of Directors

**Peter Fellner, PhD**  
Chairman

**Prof Sir Tom Blundell, FRS**  
University of Cambridge, UK  
Co-Founder

**Martin Buckland, DPhil MBA**  
Chief Business Officer

**Stephen Bunting, PhD**  
Abingworth

**Amos Goren, MBA**  
Apax Partners

**Harren Jhoti, PhD**  
Founder and CEO

**Ismail Kola, PhD**  
UCB

**Ned Olivier**  
Oxford Bioscience Partners

**Peter Ringrose, PhD**  
Ex-BMS/Pfizer


**Patrick Van Beneden, MSci**  
GIMV

### The Company


Astex Therapeutics is the world leader in fragment based drug discovery - the most important advance in drug discovery chemistry in the last 20 years.

- Astex is using its innovative fragment-based drug discovery platform, Pyramid™, to identify and develop new medicines primarily for the treatment of cancer and viral infections.
- The company has established a clinical stage pipeline of novel drug candidates.
- All of the products being developed by Astex have been discovered through the use of the company's proprietary technologies.
- Based on current output, the company expects Pyramid™ to continue to deliver a steady stream of IND candidates from internal and partnered programmes.

### Pipeline



### Partnered Projects



### Strategic Alliances

- In addition to driving the growth of Astex's in-house pipeline, Pyramid™ underpins the company's drug discovery and development collaborations with major pharmaceutical companies.
- The total value of fees, funding and milestone payments under these collaborations potentially exceeds \$1 billion, excluding royalties.
- Astex has current collaborations with GSK and Janssen Pharmaceutica and has successfully completed collaborations with companies including Astellas, AstraZeneca, Bayer-Schering, Boehringer Ingelheim, Mitsubishi Tanabe Pharma and Novartis.



#### Scientific Advisors

**Prof Sir Tom Blundell, FRS**  
University of Cambridge, UK  
Co-Founder

**Prof Chris Abell, PhD**  
University of Cambridge, UK

**Simon Campbell, CBE FRS**  
Ex-Pfizer, ex-President of the  
Royal Society of Chemistry

**Barry Furr, OBE MA (Cantab)  
PhD**  
Ex-AstraZeneca

**Prof Steve Ley, FRS**  
University of Cambridge, UK

**Dr. Herbie Newell, PhD**  
Northern Inst. for Cancer Research,  
Newcastle upon Tyne, UK

**Prof Robert Stroud, PhD**  
University of California  
San Francisco

**Prof Ashok Venkitaraman, MD**  
University of Cambridge, UK

#### Clinical Consultants

**Prof Hilary Calvert, MB BChir  
MSc MD FRCP FMedSci**  
Northern Inst. for Cancer Research,  
Newcastle upon Tyne, UK

**Prof Stan Kaye, BSc MD FRCP  
FRCR FRSE FMedSci**  
Royal Marsden Hospital, UK

**Prof Ian Judson, MA MB  
BChir MD FRCP**  
Royal Marsden Hospital, UK

**Prof Hagop Kantarjian, MD  
PhD MD**  
MD Anderson Cancer Center, USA

**Dr. Daruka Mahadevan, MD  
PhD**  
University of Arizona, USA

**Prof Lesley Seymour, MD  
FCP(SA) FRCCP**  
Queens University, Canada


#### Investors

Abingworth  
Oxford Biosciences  
Advent International  
Alta Partners  
Apax  
GIMV  
HypoVereinsbank  
Bayer Schering  
GlaxoSmithKline  
J&J Development Corporation  
Novartis  
University of Cambridge  
Wellcome Trust

## Pyramid™: Fragment Based Drug Discovery

Astex has established its integrated, fragment-based drug discovery approach, **Pyramid™**, as an industry-leading platform that rapidly delivers tailored, high-quality small molecule drug leads with enhanced therapeutic potential.

**Pyramid™** defines a process by which a range of high throughput biophysical and computational techniques are used to experimentally characterise the interactions of very low molecular weight compounds (fragments) with their target proteins. These fragments can then be rapidly and efficiently optimised into potent lead compounds using iterative medicinal chemistry guided and informed by structure-based design as illustrated below.



The productivity of **Pyramid™** has allowed the company to generate a robust pipeline including novel “first-in-class” drug compounds and potential “best-in-class” drug candidates which the company is advancing independently and through valuable strategic partnerships with industry leaders such as AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica (a Johnson & Johnson company) and Novartis.

## Company History and Location

Astex was established in 1999 and has raised more than £80 million in equity finance. The company operates from a state-of-the-art, 36,000 sq. ft. facility on the Cambridge Science Park, Cambridge, United Kingdom



## Publication Highlights

- Astex scientists have published in world-leading journals including *Nature* and *Science*
- Astex's landmark Pyramid™ technology paper was the 2<sup>nd</sup> most cited article in *J. Med. Chem.* in 2005
- Astex had 3 papers in the American Chemical Society's list of the top 10 most cited papers in *J. Med. Chem.* in 2007

## Contact Details

### Astex Therapeutics Limited

436 Cambridge Science Park  
Milton Road  
Cambridge CB4 0QA  
United Kingdom

Tel: +44 (0)1223 226200

Fax: +44 (0)1223 226201

Email: [info@astex-therapeutics.com](mailto:info@astex-therapeutics.com)